
Aldeyra Therapeutics (ALDX) Stock Forecast & Price Target
Aldeyra Therapeutics (ALDX) Analyst Ratings
Bulls say
Aldeyra Therapeutics is viewed favorably because Reproxalap has shown compelling activity across nine adequate and well-controlled trials, with five meeting all multiplicity-controlled primary endpoints, while the FDA dispute remains centered on interpretation rather than a request for new studies. The company’s RASP platform and first-mover work on irreversible scavengers create a differentiated pipeline spanning dry eye disease, allergic conjunctivitis, and other inflammatory disorders, supported by large underserved markets and a strategy to conserve resources by continuing ADX-2191 only in primary vitreoretinal lymphoma. Financially, the current operational cash runway is anticipated to last into 2029, and management expects ABBV could execute the licensing agreement if Reproxalap is ultimately approved.
Bears say
Aldeyra Therapeutics is facing a deeply challenged regulatory path for reproxalap, with the FDA issuing a CRL on April 3, 2025, and another CRL today after repeated resubmissions failed to convince regulators of efficacy. The company’s reliance on a single chamber trial, despite a field trial and later FDA requests for additional study documentation, underscores inconsistent clinical results and methodological concerns rather than a durable evidentiary package. With no approved product revenue highlighted and a pipeline still dependent on early- and late-stage candidates such as ADX248, ADX743, and ADX2191, the fundamental risk remains high because future value is heavily tied to uncertain clinical and regulatory outcomes.
This aggregate rating is based on analysts' research of Aldeyra Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Aldeyra Therapeutics (ALDX) Analyst Forecast & Price Prediction
Start investing in Aldeyra Therapeutics (ALDX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Aldeyra Therapeutics (ALDX) Forecast
Aldeyra Therapeutics (ALDX) Analyst Forecast & Price Prediction
Start investing in Aldeyra Therapeutics (ALDX)
Order type
Buy in
Order amount
Est. shares
0 shares